In addition, Razavi et al. reported an enrichment of alterations in multiple genes among samples from BC patients with CDK4/6 inhibitor resistance, such as PI3K/AKT, RB1, Hippo signaling genes, CDKN2A, and FGFR1 [83]. This evidence concerns the gene RB1 and breast cancer.